After 40 years in development, the first TIL therapy received accelerated approval from the FDA for advanced melanoma. The therapy, called Amtagvi or lifileucel, is the first cell therapy approved for a solid tumor. During a phase 2 clinical trial, 31% of patients responded to the therapy, with 42% of those patients continuing to respond for 18 months or longer. This is a game-changing moment for the field of immunotherapy, particularly for solid tumors. Researchers hope that this approval is the first of many improvements to come and marks a significant achievement in the treatment of cancer.
Source link
In ‘major milestone,’ FDA approves first cell therapy for solid tumors
